Imprimis Pharmaceuticals In Intellectual Property Deal

San Diego-based biopharmaceuticals developer Imprimis Pharmaceuticals announced this morning that it has acquired intellectual property from Novel Drug Solutions and Eye Care Northwest. Imprimis said the IP includes a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Financial terms of the acquisition were not disclosed. Imprimis said the acquisition allows it to pursue commercial development in the cataract surgery market.